Page 4 - Repligen Daily News Today

Repligen (NASDAQ:RGEN – Free Report) had its price target lifted by JPMorgan Chase & Co. from $170.00 to $210.00 in a research report released on Wednesday, Benzinga reports. The brokerage currently has an overweight rating on the biotechnology company’s stock. A number of other equities analysts also recently issued reports on the company. Stifel Nicolaus […]

Granite Bay Wealth Management LLC acquired a new stake in shares of Repligen Co. (NASDAQ:RGEN – Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 30,744 shares of the biotechnology company’s stock, valued at approximately $5,026,000. Granite Bay Wealth Management LLC owned […]

Brown Capital Management LLC grew its position in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 0.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,445,213 shares of the biotechnology company’s stock after buying an additional 4,845 shares during the period. Repligen […]

Repligen (NASDAQ:RGEN – Get Free Report) was downgraded by Benchmark from a “buy” rating to a “hold” rating in a report released on Monday, FinViz reports. Other equities research analysts also recently issued research reports about the company. UBS Group lowered their price target on Repligen from $210.00 to $170.00 and set a “buy” rating […]

Shares of Repligen Co. (NASDAQ:RGEN – Get Free Report) have earned an average rating of “Moderate Buy” from the eleven brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 1-year price objective among […]

Artisan Partners Limited Partnership lifted its holdings in Repligen Co. (NASDAQ:RGEN – Free Report) by 14.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,399,066 shares of the biotechnology company’s stock after purchasing an additional 177,485 shares during […]

Repligen Co. (NASDAQ:RGEN – Get Free Report) insider Christine Gebski sold 3,788 shares of the stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $147.13, for a total transaction of $557,328.44. Following the transaction, the insider now owns 28,787 shares in the company, valued at […]

Repligen (NASDAQ:RGEN – Free Report) had its price objective trimmed by Royal Bank of Canada from $207.00 to $200.00 in a research note released on Wednesday morning, Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock. Other equities analysts have also issued research reports about the stock. Craig Hallum dropped […]

New York State Common Retirement Fund boosted its position in Repligen Co. (NASDAQ:RGEN – Free Report) by 1.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 436,799 shares of the biotechnology company’s stock after purchasing an additional 4,281 shares during […]

Repligen (NASDAQ:RGEN – Get Free Report) had its price target dropped by investment analysts at UBS Group from $210.00 to $170.00 in a research report issued on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. UBS Group’s target price suggests a potential upside of 24.51% from the stock’s […]